Seeking Alpha

More on McKesson (MCK +3.5%) Q3: net profit +35% to $401M, boosted by a strong performance at...

More on McKesson (MCK +3.5%) Q3: net profit +35% to $401M, boosted by a strong performance at its U.S. pharmaceutical distribution business. The company also benefits from the introduction of generic drugs as patents expires across the industry. Raises low end of FY adjusted EPS by 10 cents to $7.15-$7.35 vs consensus of $7.26. (PSS acquisition)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)